## Anssi Auvinen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7719703/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine, 2009, 360, 1320-1328.	13.9	3,540
2	Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ: British Medical Journal, 2005, 330, 223.	2.4	1,284
3	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, The, 2014, 384, 2027-2035.	6.3	1,261
4	The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: Estimates of Radiation-Related Cancer Risks. Radiation Research, 2007, 167, 396-416.	0.7	1,139
5	Prostate-Cancer Mortality at 11 Years of Follow-up. New England Journal of Medicine, 2012, 366, 981-990.	13.9	1,105
6	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
7	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	9.4	492
8	Prevalence of symptoms among patients with advanced cancer: An international collaborative study. Journal of Pain and Symptom Management, 1996, 12, 3-10.	0.6	423
9	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	9.4	408
10	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics, 2009, 41, 1116-1121.	9.4	389
11	Quality-of-Life Effects of Prostate-Specific Antigen Screening. New England Journal of Medicine, 2012, 367, 595-605.	13.9	364
12	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology, 2019, 76, 43-51.	0.9	359
13	An association of serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men. American Journal of Clinical Nutrition, 2007, 86, 714-717.	2.2	354
14	Renal effects of uranium in drinking water Environmental Health Perspectives, 2002, 110, 337-342.	2.8	345
15	Nocturia Frequency, Bother, and Quality of Life: How Often Is Too Often? A Population-Based Study in Finland. European Urology, 2010, 57, 488-498.	0.9	290
16	Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a populationâ€based evaluation. Arthritis and Rheumatism, 2001, 45, 419-423.	6.7	277
17	Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology, 2005, 64, 1874-1878.	1.5	272
18	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	9.4	264

#	Article	IF	CITATIONS
19	Prostate cancer incidence and mortality trends in 37 European countries: An overview. European Journal of Cancer, 2010, 46, 3040-3052.	1.3	260
20	Incidence of gliomas by anatomic location. Neuro-Oncology, 2007, 9, 319-325.	0.6	250
21	Large-scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. International Journal of Cancer, 2002, 97, 237-244.	2.3	247
22	Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland Environmental Health Perspectives, 1999, 107, 705-710.	2.8	236
23	The INTERPHONE study: design, epidemiological methods, and description of the study population. European Journal of Epidemiology, 2007, 22, 647-664.	2.5	225
24	Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). European Urology, 2012, 62, 745-752.	0.9	216
25	Brain Tumors and Salivary Gland Cancers Among Cellular Telephone Users. Epidemiology, 2002, 13, 356-359.	1.2	212
26	Bone as a Possible Target of Chemical Toxicity of Natural Uranium in Drinking Water. Environmental Health Perspectives, 2005, 113, 68-72.	2.8	206
27	What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women. European Urology, 2014, 65, 1211-1217.	0.9	193
28	Incidence of cancer among Finnish airline cabin attendants, 1967-92. BMJ: British Medical Journal, 1995, 311, 649-652.	2.4	189
29	Prognosis of non-specific musculoskeletal pain in preadolescents: A prospective 4-year follow-up study till adolescence. Pain, 2004, 110, 550-559.	2.0	188
30	Mobile phone use and risk of acoustic neuroma: results of the Interphone case–control study in five North European countries. British Journal of Cancer, 2005, 93, 842-848.	2.9	181
31	Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). European Urology, 2009, 56, 584-591.	0.9	180
32	European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiology, 2015, 39, S1-S10.	0.8	176
33	Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infection: A Randomized, Doubleâ€Blinded Trial among Young Finnish Men. Journal of Infectious Diseases, 2010, 202, 809-814.	1.9	168
34	Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2226-2232.	1.1	166
35	Kidney Toxicity of Ingested Uranium From Drinking Water. American Journal of Kidney Diseases, 2006, 47, 972-982.	2.1	165
36	Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet, The, 2004, 363, 1422-1426.	6.3	162

#	Article	IF	CITATIONS
37	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine, 2017, 167, 449.	2.0	160
38	Association of Repeated Exposure to Antibiotics With the Development of Pediatric Crohn's DiseaseA Nationwide, Register-based Finnish Case-Control Study. American Journal of Epidemiology, 2012, 175, 775-784.	1.6	158
39	Interpreting Trends in Prostate Cancer Incidence and Mortality in the Five Nordic Countries. Journal of the National Cancer Institute, 2007, 99, 1881-1887.	3.0	157
40	A Systematic Evaluation of Factors Associated With Nocturia—The Population-based FINNO Study. American Journal of Epidemiology, 2009, 170, 361-368.	1.6	155
41	Incidence of inflammatory bowel disease in finnish children, 1987–2003. Inflammatory Bowel Diseases, 2006, 12, 677-683.	0.9	152
42	Mobile phone use and risk of glioma in 5 North European countries. International Journal of Cancer, 2007, 120, 1769-1775.	2.3	148
43	Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology, 2000, 56, 418-422.	0.5	141
44	Treatment delay and the risk of prolonged status epilepticus. Neurology, 2005, 65, 1316-1318.	1.5	139
45	Loss of SUFU Function in Familial Multiple Meningioma. American Journal of Human Genetics, 2012, 91, 520-526.	2.6	137
46	Mortality from diseases other than cancer following low doses of ionizing radiation: results from the 15-Country Study of nuclear industry workers. International Journal of Epidemiology, 2007, 36, 1126-1135.	0.9	135
47	Increased Cardiovascular and Cancer Mortality after Radioiodine Treatment for Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2190-2196.	1.8	132
48	Epilepsy-related clinical characteristics and mortality. Neurology, 2014, 83, 1968-1977.	1.5	131
49	Incidence of cancer among Nordic airline pilots over five decades: occupational cohort study. BMJ: British Medical Journal, 2002, 325, 567-567.	2.4	129
50	ls Nocturia Equally Common Among Men and Women? A Population Based Study in Finland. Journal of Urology, 2006, 175, 596-600.	0.2	128
51	The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: Design, Epidemiological Methods and Descriptive Results. Radiation Research, 2007, 167, 361-379.	0.7	125
52	Validation of short term recall of mobile phone use for the Interphone study. Occupational and Environmental Medicine, 2006, 63, 237-243.	1.3	124
53	Time Trends in Brain Tumor Incidence Rates in Denmark, Finland, Norway, and Sweden, 1974-2003. Journal of the National Cancer Institute, 2009, 101, 1721-1724.	3.0	121
54	Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. British Journal of Cancer, 1997, 75, 301-305.	2.9	120

#	Article	IF	CITATIONS
55	Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer, 2007, 109, 1972-1979.	2.0	120
56	Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. Journal of the National Cancer Institute, 2015, 107, 366.	3.0	120
57	Prevalence of Symptoms Related to Interstitial Cystitis in Women: A Population Based Study in Finland. Journal of Urology, 2002, 168, 139-143.	0.2	119
58	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	1.4	118
59	Interstitial cystitis–like urinary symptoms among patients with Sjögren's syndrome: a population-based study in Finland. American Journal of Medicine, 2003, 115, 62-65.	0.6	117
60	Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. Journal of Neuro-Oncology, 2006, 80, 1-7.	1.4	116
61	Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. Cell, 2018, 174, 576-589.e18.	13.5	116
62	Incidence trends of pediatric inflammatory bowel disease in Finland, 1987–2003, a nationwide study. Inflammatory Bowel Diseases, 2011, 17, 1778-1783.	0.9	112
63	Indoor Radon Exposure and Risk of Lung Cancer: a Nested CaseControl Study in Finland. Journal of the National Cancer Institute, 1996, 88, 966-972.	3.0	111
64	Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. European Urology, 2015, 68, 885-890.	0.9	111
65	Incidence trends of adult primary intracerebral tumors in four Nordic countries. International Journal of Cancer, 2004, 108, 450-455.	2.3	108
66	Allergic Conditions and Brain Tumor Risk. American Journal of Epidemiology, 2007, 166, 941-950.	1.6	106
67	Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968-1997. International Journal of Cancer, 2005, 117, 996-1001.	2.3	104
68	Bidirectional Relationship Between Depression and Erectile Dysfunction. Journal of Urology, 2007, 177, 669-673.	0.2	104
69	Risk factors for development of non-specific musculoskeletal pain in preteens and early adolescents: a prospective 1-year follow-up study. BMC Musculoskeletal Disorders, 2007, 8, 46.	0.8	100
70	Onset, prognosis and risk factors for widespread pain in schoolchildren: A prospective 4-year follow-up study. Pain, 2008, 138, 681-687.	2.0	100
71	Cancer screening: Evidence and practice in Europe 2008. European Journal of Cancer, 2008, 44, 1404-1413.	1.3	100
72	Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study. American Journal of Epidemiology, 2008, 168, 925-931.	1.6	100

#	Article	IF	CITATIONS
73	Mobile Phone Use and Incidence of Glioma in the Nordic Countries 1979–2008. Epidemiology, 2012, 23, 301-307.	1.2	100
74	Mortality from cancer and other causes among male airline cockpit crew in Europe. International Journal of Cancer, 2003, 106, 946-952.	2.3	99
75	Prospective Evaluation Plan for Randomised Trials of Prostate Cancer Screening. Journal of Medical Screening, 1996, 3, 97-104.	1.1	98
76	Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies. Current Drug Safety, 2013, 8, 333-348.	0.3	95
77	Risks from CT scans—what do recent studies tell us?. Journal of Radiological Protection, 2014, 34, E1.	0.6	95
78	Prostate Cancer Mortality in the Finnish Randomized Screening Trial. Journal of the National Cancer Institute, 2013, 105, 719-725.	3.0	94
79	PREVALENCE OF CLINICALLY CONFIRMED INTERSTITIAL CYSTITIS IN WOMEN: A POPULATION BASED STUDY IN FINLAND. Journal of Urology, 2005, 174, 581-583.	0.2	89
80	Risk of Subsequent Cancer Following Breast Cancer in Men. Journal of the National Cancer Institute, 2002, 94, 1330-1332.	3.0	88
81	Mortality from Cancer and Other Causes among Airline Cabin Attendants in Europe: A Collaborative Cohort Study in Eight Countries. American Journal of Epidemiology, 2003, 158, 35-46.	1.6	88
82	Vitamin D fortification as public health policy: significant improvement in vitamin D status in young Finnish men. European Journal of Clinical Nutrition, 2006, 60, 1035-1038.	1.3	88
83	Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. International Journal of Cancer, 2010, 127, 1650-1659.	2.3	88
84	The Prevalence of Clinically Meaningful Overactive Bladder: Bother and Quality of Life Results from the Population-Based FINNO Study. European Urology, 2011, 59, 629-636.	0.9	88
85	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
86	Long-term health outcomes in pediatric inflammatory bowel disease: A population-based study. Inflammatory Bowel Diseases, 2009, 15, 56-62.	0.9	84
87	Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. American Journal of Medicine, 2000, 109, 712-717.	0.6	83
88	European Code against Cancer 4th Edition: Ultraviolet radiation and cancer. Cancer Epidemiology, 2015, 39, S75-S83.	0.8	83
89	Reproductive Factors and Risk of Meningioma and Glioma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2663-2670.	1.1	81
90	A randomized trial of choice of treatment in prostate cancer: the effect of intervention on the treatment chosen. BJU International, 2004, 93, 52-56.	1.3	80

#	Article	IF	CITATIONS
91	Systematic review of wireless phone use and brain cancer and other head tumors. Bioelectromagnetics, 2012, 33, 187-206.	0.9	80
92	Effect of life-style factors on incidence of erectile dysfunction. International Journal of Impotence Research, 2004, 16, 389-394.	1.0	77
93	Radon and other natural radionuclides in drinking water and risk of stomach cancer: A case-cohort study in Finland. International Journal of Cancer, 2005, 114, 109-113.	2.3	77
94	XRCC1 and XRCC3 variants and risk of glioma and meningioma. Journal of Neuro-Oncology, 2008, 88, 135-142.	1.4	77
95	Cosmic radiation and cancer mortality among airline pilots: results from a European cohort study (ESCAPE). Radiation and Environmental Biophysics, 2004, 42, 247-256.	0.6	76
96	Angiosarcoma after radiotherapy: a cohort study of 332 163 Finnish cancer patients. British Journal of Cancer, 2007, 97, 115-117.	2.9	76
97	URINE, HAIR, AND NAILS AS INDICATORS FOR INGESTION OF URANIUM IN DRINKING WATER. Health Physics, 2005, 88, 229-242.	0.3	75
98	<i>HOXB13</i> G84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 452-460.	1.1	75
99	Overexpression of p53 and long-term survival in colon carcinoma. British Journal of Cancer, 1994, 70, 293-296.	2.9	74
100	Social Class and Cancer Patient Survival in Finland. American Journal of Epidemiology, 1995, 142, 1089-1102.	1.6	73
101	European randomized study of prostate cancer screening: first-year results of the Finnish trial. British Journal of Cancer, 1999, 79, 1210-1214.	2.9	73
102	Incidence of bone and soft tissue sarcoma after radiotherapy: A cohort study of 295,712 Finnish cancer patients. International Journal of Cancer, 2006, 118, 1017-1021.	2.3	73
103	Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology, 2002, 60, 846-850.	0.5	71
104	Mortality from cancer and other causes in commercial airline crews: a joint analysis of cohorts from 10 countries. Occupational and Environmental Medicine, 2014, 71, 313-322.	1.3	68
105	Birth Rate among Patients with Epilepsy: A Nationwide Population-based Cohort Study in Finland. American Journal of Epidemiology, 2004, 159, 1057-1063.	1.6	67
106	Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma. Human Molecular Genetics, 2008, 17, 800-805.	1.4	67
107	Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-postitive PSA results in prostate cancer screening. International Journal of Cancer, 2004, 111, 310-315.	2.3	66
108	A comprehensive study of the association between the ECFR and ERBB2 genes and glioma risk. Acta OncolA <sup>3</sup> gica, 2010, 49, 767-775.	0.8	66

#	Article	IF	CITATIONS
109	An international prospective cohort study of mobile phone users and health (Cosmos): Design considerations and enrolment. Cancer Epidemiology, 2011, 35, 37-43.	0.8	66
110	Panel discussion does not improve reliability of peer review for medical research grant proposals. Journal of Clinical Epidemiology, 2012, 65, 47-52.	2.4	66
111	Lower Limb Pain in a Preadolescent Population: Prognosis and Risk Factors for ChronicityA Prospective 1- and 4-Year Follow-up Study. Pediatrics, 2005, 116, 673-681.	1.0	65
112	Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. European Journal of Cancer, 2013, 49, 938-945.	1.3	65
113	Low-dose ionising radiation and cardiovascular diseases – Strategies for molecular epidemiological studies in Europe. Mutation Research - Reviews in Mutation Research, 2015, 764, 90-100.	2.4	64
114	Do Confounding or Selection Factors of Residential Wiring Codes and Magnetic Fields Distort Findings of Electromagnetic Fields Studies?. Epidemiology, 2000, 11, 189-198.	1.2	64
115	Breast cancer risk among Finnish cabin attendants: a nested case-control study. Occupational and Environmental Medicine, 2005, 62, 488-493.	1.3	63
116	Well water radioactivity and risk of cancers of the urinary organs. Environmental Research, 2006, 102, 333-338.	3.7	63
117	Insulin-Like Growth Factor I Is Not a Useful Marker of Prostate Cancer in Men with Elevated Levels of Prostate-Specific Antigen. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2744-2747.	1.8	63
118	Cognitive Impairment in Systemic Lupus Erythematosus and Neuropsychiatric Systemic Lupus Erythematosus: A Population-Based Neuropsychological Study. Journal of Clinical and Experimental Neuropsychology, 2003, 25, 145-151.	0.8	62
119	Determinants of mobile phone output power in a multinational study: implications for exposure assessment. Occupational and Environmental Medicine, 2009, 66, 664-671.	1.3	62
120	A correlation study of eye lens dose and personal dose equivalent for interventional cardiologists. Radiation Protection Dosimetry, 2013, 157, 561-569.	0.4	62
121	Is the Prevalence of Overactive Bladder Overestimated? A Population-Based Study in Finland. PLoS ONE, 2007, 2, e195.	1.1	61
122	Nocturia and Obesity: A Population-based Study in Finland. American Journal of Epidemiology, 2006, 163, 1003-1011.	1.6	60
123	Meningioma and mobile phone usea collaborative case-control study in five North European countries. International Journal of Epidemiology, 2008, 37, 1304-1313.	0.9	59
124	Rationale for randomised trials of prostate cancer screening. European Journal of Cancer, 1999, 35, 262-271.	1.3	58
125	Epidemiologic Studies Of Pilots And Aircrew. Health Physics, 2000, 79, 576-584.	0.3	58
126	Quantifying the Impact of Selection Bias Caused by Nonparticipation in a Case–Control Study of Mobile Phone Use. Annals of Epidemiology, 2009, 19, 33-41.e1.	0.9	58

#	Article	IF	CITATIONS
127	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	0.9	58
128	Measuring social class differences in cancer patient survival: is it necessary to control for social class differences in general population mortality? A Finnish population-based study. Journal of Epidemiology and Community Health, 1998, 52, 727-734.	2.0	57
129	Sensitivity in cancer screening. Journal of Medical Screening, 2007, 14, 174-177.	1.1	57
130	Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia, 2017, 60, 1691-1703.	2.9	57
131	An International Case-Control Study of Glutathione Transferase and Functionally Related Polymorphisms and Risk of Primary Adult Brain Tumors. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 559-565.	1.1	56
132	Comprehensive Analysis of DNA Repair Gene Variants and Risk of Meningioma. Journal of the National Cancer Institute, 2008, 100, 270-276.	3.0	56
133	Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostateâ€specific antigen ( <scp>PSA</scp> ) concentration in the <scp>F</scp> innish prostate cancer screening trial. BJU International, 2013, 112, 735-741.	1.3	56
134	The efficacy of prostateâ€specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer, 2018, 124, 1197-1206.	2.0	56
135	The Estonian Study of Chernobyl Cleanup Workers: II. Incidence of Cancer and Mortality. Radiation Research, 1997, 147, 653.	0.7	55
136	CHEK2 1100delC is not a risk factor for male breast cancer population. International Journal of Cancer, 2004, 108, 475-476.	2.3	55
137	An International Case-Control Study of <i>Interleukin-4Rα, Interleukin-13</i> , and <i>Cyclooxygenase-2</i> Polymorphisms and Glioblastoma Risk. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2448-2454.	1.1	55
138	Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. Journal of Neuro-Oncology, 2007, 82, 229-237.	1.4	55
139	False-positive screening results in the European randomized study of screening for prostate cancer. European Journal of Cancer, 2011, 47, 2698-2705.	1.3	55
140	Lens opacities among physicians occupationally exposed to ionizing radiation – a pilot study in Finland. Scandinavian Journal of Work, Environment and Health, 2011, 37, 237-243.	1.7	55
141	Social class and colon cancer survival in finland. Cancer, 1992, 70, 402-409.	2.0	54
142	Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. British Journal of Cancer, 2009, 101, 843-848.	2.9	54
143	Lead-time in prostate cancer screening (Finland). Cancer Causes and Control, 2002, 13, 279-285.	0.8	53
144	Uranium and other natural radionuclides in drinking water and risk of leukemia: a case-cohort study in Finland. Cancer Causes and Control, 2002, 13, 825-829.	0.8	53

#	Article	IF	CITATIONS
145	Lead-time in the European Randomised Study of Screening for Prostate Cancer. European Journal of Cancer, 2010, 46, 3102-3108.	1.3	53
146	Depressive Symptoms Increase the Incidence of Nocturia: Tampere Aging Male Urologic Study (TAMUS). Journal of Urology, 2008, 179, 1897-1901.	0.2	52
147	Cancer incidence among Nordic airline cabin crew. International Journal of Cancer, 2012, 131, 2886-2897.	2.3	52
148	CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis. Current Drug Safety, 2013, 8, 296-332.	0.3	52
149	Effect of Nonsteroidal Anti-Inflammatory Drug Use on the Incidence of Erectile Dysfunction. Journal of Urology, 2006, 175, 1812-1816.	0.2	51
150	The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International, 2018, 121, 737-744.	1.3	51
151	The Impact of Nocturia on Mortality: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 486-495.	0.2	51
152	Prevalence and Severity of Erectile Dysfunction in 50 to 75-Year-Old Finnish Men. Journal of Urology, 2003, 170, 2342-2344.	0.2	50
153	Selection Bias Due to Differential Participation in a Case–Control Study of Mobile Phone Use and Brain Tumors. Annals of Epidemiology, 2005, 15, 321-325.	0.9	50
154	Meta-analysis of mobile phone use and intracranial tumors. Scandinavian Journal of Work, Environment and Health, 2006, 32, 171-177.	1.7	50
155	Do Recorded Doses Overestimate True Doses Received by Chernobyl Cleanup Workers? Results of Cytogenetic Analyses of Estonian Workers by Fluorescence In Situ Hybridization. Radiation Research, 1998, 150, 237.	0.7	48
156	Hereditary Minisatellite Mutations among the Offspring of Estonian Chernobyl Cleanup Workers. Radiation Research, 2003, 159, 651-655.	0.7	48
157	Functional Polymorphisms in Folate Metabolism Genes Influence the Risk of Meningioma and Glioma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1195-1202.	1.1	48
158	Assessment of causes of death in a prostate cancer screening trial. International Journal of Cancer, 2008, 122, 413-417.	2.3	47
159	Increased longâ€ŧerm cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clinical Endocrinology, 2008, 68, 450-457.	1.2	47
160	Exogenous sex hormone use and risk of meningioma: a population-based case–control study in Finland. Cancer Causes and Control, 2010, 21, 2149-2156.	0.8	47
161	Interaction Between 5 Genetic Variants and Allergy in Glioma Risk. American Journal of Epidemiology, 2010, 171, 1165-1173.	1.6	47
162	Diabetes and Breast Cancer Subtypes. PLoS ONE, 2017, 12, e0170084.	1.1	47

#	Article	IF	CITATIONS
163	Thyroid Nodularity and Cancer among Chernobyl Cleanup Workers from Estonia. Radiation Research, 1997, 147, 225.	0.7	46
164	The Common D302H Variant of CASP8 Is Associated with Risk of Glioma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 987-989.	1.1	45
165	Estimation of Prostate Cancer Risk on the Basis of Total and Free Prostate-Specific Antigen, Prostate Volume and Digital Rectal Examination. European Urology, 2002, 41, 619-627.	0.9	44
166	Effects of Age, Comorbidity and Lifestyle Factors on Erectile Function: Tampere Ageing Male Urological Study (TAMUS). European Urology, 2004, 45, 628-633.	0.9	44
167	Cardiovascular drug use and the incidence of erectile dysfunction. International Journal of Impotence Research, 2007, 19, 208-212.	1.0	44
168	Regular Intercourse Protects Against Erectile Dysfunction: Tampere Aging Male Urologic Study. American Journal of Medicine, 2008, 121, 592-596.	0.6	44
169	Smoking and Bladder Symptoms in Women. Obstetrics and Gynecology, 2011, 118, 643-648.	1.2	44
170	European Code against Cancer 4th Edition: Ionising and non-ionising radiation and cancer. Cancer Epidemiology, 2015, 39, S93-S100.	0.8	44
171	Multidisciplinary European Low Dose Initiative (MELODI): strategic research agenda for low dose radiation risk research. Radiation and Environmental Biophysics, 2018, 57, 5-15.	0.6	44
172	Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium. European Journal of Epidemiology, 2018, 33, 965-976.	2.5	44
173	Cancer incidence among 10,211 airline pilots: a Nordic study. Aviation, Space, and Environmental Medicine, 2003, 74, 699-706.	0.6	44
174	EFFECT OF LOWER URINARY TRACT SYMPTOMS ON THE INCIDENCE OF ERECTILE DYSFUNCTION. Journal of Urology, 2005, 174, 205-209.	0.2	43
175	Incidence of Nocturia in 50 to 80-Year-Old Finnish Men. Journal of Urology, 2006, 176, 2541-2545.	0.2	43
176	ls the incidence of meningiomas underestimated? A regional survey. British Journal of Cancer, 2008, 99, 182-184.	2.9	43
177	Health coaching by telephony to support self-care in chronic diseases: clinical outcomes from The TERVA randomized controlled trial. BMC Health Services Research, 2012, 12, 147.	0.9	43
178	Cancer Incidence and Mortality in Patients Treated Either With RAI or Thyroidectomy for Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3710-3717.	1.8	43
179	Cancer consequences of the Chernobyl accident in Europe outside the former USSR: A review. , 1996, 67, 343-352.		42
180	Congenital structural anomalies in offspring of women with epilepsy—a population-based cohort study in Finland. International Journal of Epidemiology, 2006, 35, 280-287.	0.9	42

#	Article	IF	CITATIONS
181	Family History and Prostate Cancer Screening With Prostate-Specific Antigen. Journal of Clinical Oncology, 2002, 20, 2658-2663.	0.8	41
182	Effect of chronic diseases on incidence of erectile dysfunction. Urology, 2003, 62, 1097-1102.	0.5	41
183	Anticardiolipin and antinuclear antibodies in epilepsy—a population-based cross-sectional study. Epilepsy Research, 2004, 58, 13-18.	0.8	41
184	Cancer risk among chernobyl cleanup workers in Estonia and Latvia, 1986–1998. International Journal of Cancer, 2006, 119, 162-168.	2.3	41
185	Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scandinavian Journal of Urology, 2017, 51, 5-12.	0.6	41
186	Diagnostic Value of Free Prostate-Specific Antigen among Men with a Prostate-Specific Antigen Level of <3.01¼g per Liter. European Urology, 2008, 54, 362-370.	0.9	40
187	The Effects of Lifestyle Factors on the Incidence of Nocturia. Journal of Urology, 2008, 180, 2059-2062.	0.2	40
188	Cardiovascular Morbidity and Mortality After Treatment of Hyperthyroidism with Either Radioactive Iodine or Thyroidectomy. Thyroid, 2018, 28, 1111-1120.	2.4	40
189	Three-Year Results of the Finnish Prostate Cancer Screening Trial. Journal of the National Cancer Institute, 2001, 93, 552-553.	3.0	39
190	Second Round Results of the Finnish Population-Based Prostate Cancer Screening Trial. Clinical Cancer Research, 2004, 10, 2231-2236.	3.2	39
191	Mortality by clinical characteristics in a tertiary care cohort of adult patients with chronic epilepsy. Epilepsia, 2012, 53, e212-4.	2.6	39
192	Prostate cancer risk prediction using a polygenic risk score. Scientific Reports, 2020, 10, 17075.	1.6	39
193	False-positive screening results in the Finnish prostate cancer screening trial. British Journal of Cancer, 2010, 102, 469-474.	2.9	38
194	Location of Gliomas in Relation to Mobile Telephone Use: A Case-Case and Case-Specular Analysis. American Journal of Epidemiology, 2011, 174, 2-11.	1.6	38
195	Celiac disease-related antibodies in an epilepsy cohort and matched reference population. Epilepsy and Behavior, 2005, 6, 388-392.	0.9	37
196	Balancing the harms and benefits of early detection of prostate cancer. Cancer, 2010, 116, 4857-4865.	2.0	37
197	Background radiation and childhood leukemia: A nationwide registerâ€based caseâ€control study. International Journal of Cancer, 2016, 139, 1975-1982.	2.3	37
198	Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. European Urology Focus, 2017, 3, 212-220.	1.6	37

#	Article	IF	CITATIONS
199	<p>Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time</p> . Clinical Epidemiology, 2019, Volume 11, 923-932.	1.5	37
200	Antiepileptic drug use and birth rate in patients with epilepsy–a population-based cohort study in Finland. Human Reproduction, 2006, 21, 2290-2295.	0.4	36
201	Long-term mortality risk by cause of death in newly diagnosed patients with epilepsy in Finland: a nationwide register-based study. European Journal of Epidemiology, 2013, 28, 981-990.	2.5	36
202	Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer. American Journal of Epidemiology, 2016, 184, 720-731.	1.6	36
203	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. European Journal of Epidemiology, 2017, 32, 521-527.	2.5	36
204	Biodosimetry of Chernobyl Cleanup Workers from Estonia and Latvia Using the Glycophorin A In Vivo Somatic Cell Mutation Assay. Radiation Research, 1997, 147, 215.	0.7	35
205	European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. Cancer Epidemiology, 2015, 39, S107-S119.	0.8	35
206	Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. Clinical Cancer Research, 2016, 22, 243-249.	3.2	35
207	Clinical and epidemiological observations on individual radiation sensitivity and susceptibility. International Journal of Radiation Biology, 2020, 96, 324-339.	1.0	35
208	Androgen Receptor Gene Alterations in Finnish Male Breast Cancer. Breast Cancer Research and Treatment, 2003, 77, 167-170.	1.1	34
209	Medical history, cigarette smoking and risk of acoustic neuroma: An international case-control study. International Journal of Cancer, 2007, 120, 103-110.	2.3	34
210	Reproductive factors associated with nocturia and urinary urgency in women: a population-based study in Finland. American Journal of Obstetrics and Gynecology, 2008, 199, 153.e1-153.e12.	0.7	34
211	Ionizing Radiation and Risk of Chronic Lymphocytic Leukemia in the 15-Country Study of Nuclear Industry Workers. Radiation Research, 2008, 170, 661-665.	0.7	34
212	BRCA2 Mutations in 154 Finnish Male Breast Cancer Patients. Neoplasia, 2004, 6, 541-545.	2.3	33
213	A Nationwide Cohort Study on the Incidence of Meningioma in Women Using Postmenopausal Hormone Therapy in Finland. American Journal of Epidemiology, 2012, 175, 309-314.	1.6	33
214	Headache, tinnitus and hearing loss in the international Cohort Study of Mobile Phone Use and Health (COSMOS) in Sweden and Finland. International Journal of Epidemiology, 2019, 48, 1567-1579.	0.9	33
215	Extremely Low-Frequency Magnetic Fields and Childhood Acute Lymphoblastic Leukemia: An Exploratory Analysis of Alternative Exposure Metrics. American Journal of Epidemiology, 2000, 152, 20-31.	1.6	32
216	Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. British Journal of Cancer, 2015, 113, 1086-1093.	2.9	32

#	Article	IF	CITATIONS
217	Breast and cervical cancer incidence and mortality trends in Russia 1980–2013. Cancer Epidemiology, 2018, 55, 73-80.	0.8	32
218	Long-term effect of mobile phone use on sleep quality: Results from the cohort study of mobile phone use and health (COSMOS). Environment International, 2020, 140, 105687.	4.8	32
219	Haemophilus influenzae type B vaccination and risk of childhood leukaemia in a vaccine trial in Finland. British Journal of Cancer, 2000, 83, 956-958.	2.9	31
220	Impact of Obesity on Urinary Storage Symptoms: Results from the FINNO Study. Journal of Urology, 2013, 189, 1377-1382.	0.2	31
221	Risk factors for traumatic and non-traumatic lower limb pain among preadolescents: a population-based study of Finnish schoolchildren. BMC Musculoskeletal Disorders, 2006, 7, 3.	0.8	30
222	Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. Scandinavian Journal of Urology, 2016, 50, 267-273.	0.6	30
223	Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). Haematologica, 2018, 103, 1873-1880.	1.7	30
224	Hysterectomy and subsequent risk of cancer. International Journal of Epidemiology, 1997, 26, 476-483.	0.9	29
225	No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU International, 2011, 107, 1912-1917.	1.3	29
226	Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 66-76.	2.0	28
227	Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. Journal of Urology, 2019, 201, 486-495.	0.2	28
228	Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. British Journal of Cancer, 1996, 74, 568-572.	2.9	27
229	Impact of LUTS Using Bother Index in DAN-PSS-1 Questionnaire. European Urology, 2007, 51, 473-478.	0.9	27
230	Reducing overestimation in reported mobile phone use associated with epidemiological studies. Bioelectromagnetics, 2008, 29, 559-563.	0.9	27
231	MNS16A minisatellite genotypes in relation to risk of glioma and meningioma and to glioblastoma outcome. International Journal of Cancer, 2009, 125, 968-972.	2.3	27
232	Site-specific cancer risk in the Baltic cohort of Chernobyl cleanup workers, 1986–2007. European Journal of Cancer, 2013, 49, 2926-2933.	1.3	27
233	Breast self-examination and survival from breast cancer. Breast Cancer Research and Treatment, 1996, 38, 161-168.	1.1	26
234	USE OF THE COMPLEX BETWEEN PROSTATE SPECIFIC ANTIGEN AND α1-PROTEASE INHIBITOR FOR SCREENING PROSTATE CANCER. Journal of Urology, 2000, 164, 1956-1960.	0.2	26

#	Article	IF	CITATIONS
235	Frequent amplification and overexpression of CCND1 in male breast cancer. International Journal of Cancer, 2004, 111, 968-971.	2.3	26
236	Association between the Bothersomeness of Lower Urinary Tract Symptoms and the Prevalence of Erectile Dysfunction. Journal of Sexual Medicine, 2005, 2, 438-444.	0.3	26
237	Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. British Journal of Cancer, 2014, 111, 1421-1431.	2.9	26
238	Cardiovascular morbidity and mortality in surgically treated hyperthyroidism – a nationâ€wide cohort study with a longâ€ŧerm followâ€up. Clinical Endocrinology, 2014, 80, 743-750.	1.2	26
239	Glycophorin A biodosimetry in Chernobyl cleanup workers from the Baltic countries. BMJ: British Medical Journal, 1996, 312, 1078-1079.	2.4	26
240	Smoking Cessation Intervention in Rural Kerala, India: Findings of a Randomised Controlled Trial. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6797-6802.	0.5	26
241	Population exposure to ultraviolet radiation in Finland 1920–1995: Exposure trends and a time-series analysis of exposure and cutaneous melanoma incidence. Environmental Research, 2006, 101, 123-131.	3.7	25
242	HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Research, 2009, 11, R37.	2.2	25
243	Incidence trends of vestibular schwannomas in Denmark, Finland, Norway and Sweden in 1987–2007. British Journal of Cancer, 2011, 105, 1069-1075.	2.9	25
244	A randomized trial of the choice of treatment in prostate cancer: design and baseline characteristics. BJU International, 2001, 88, 708-715.	1.3	24
245	Serum IgA, IgG, and IgM concentrations in patients with epilepsy and matched controls: a cohort-based cross-sectional study. Epilepsy and Behavior, 2005, 6, 191-195.	0.9	24
246	Erectile dysfunction influences the subsequent incidence of lower urinary tract symptoms and bother. International Journal of Impotence Research, 2007, 19, 317-320.	1.0	24
247	Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. Journal of Urology, 2017, 198, 50-57.	0.2	24
248	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	2.6	24
249	Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. International Journal of Cancer, 2004, 111, 940-943.	2.3	23
250	Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer. Breast Cancer Research and Treatment, 2010, 122, 553-566.	1.1	23
251	The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case–control study. Cancer Causes and Control, 2011, 22, 1445-1452.	0.8	23
252	A Framework for Estimating Radiation-Related Cancer Risks in Japan from the 2011 Fukushima Nuclear Accident. Radiation Research, 2014, 182, 556.	0.7	23

#	Article	IF	CITATIONS
253	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer, 2016, 122, 3386-3393.	2.0	23
254	Re. Epidemiology, 2016, 27, e20-e21.	1.2	23
255	Risk of Causeâ€&pecific Death in Individuals with Cancer—Modifying Role Diabetes, Statins and Metformin. International Journal of Cancer, 2017, 141, 2437-2449.	2.3	23
256	Long-term strategies for thyroid health monitoring after nuclear accidents: recommendations from an Expert Group convened by IARC. Lancet Oncology, The, 2018, 19, 1280-1283.	5.1	23
257	Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium. Cancer Epidemiology, 2019, 59, 158-165.	0.8	23
258	Mortality after Cerebral Angiography with or without Radioactive Thorotrast: An International Cohort of 3,143 Two-Year Survivors. Radiation Research, 2001, 156, 136-150.	0.7	22
259	Relationship between smoking and erectile dysfunction. International Journal of Impotence Research, 2005, 17, 164-169.	1.0	22
260	Epidemiological risk assessment of mobile phones and cancer: where can we improve?. European Journal of Cancer Prevention, 2006, 15, 516-523.	0.6	22
261	Chernobyl cleanup workers from Estonia: follow-up for cancer incidence and mortality. Journal of Radiological Protection, 2013, 33, 395-411.	0.6	22
262	Women treated for epilepsy during pregnancy: outcomes from a nationwide populationâ€based cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 812-820.	1.3	22
263	Retrospective dose estimates in Estonian Chernobyl clean-up workers by means of FISH. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1996, 369, 7-12.	1.2	21
264	Health-Related Quality of Life in the Finnish Trial of Screening for Prostate Cancer. European Urology, 2014, 65, 39-47.	0.9	21
265	Sotalol, but not digoxin is associated with decreased prostate cancer risk: A populationâ€based case–control study. International Journal of Cancer, 2015, 137, 1187-1195.	2.3	21
266	The Intracranial Distribution of Cliomas in Relation to Exposure From Mobile Phones: Analyses From the INTERPHONE Study. American Journal of Epidemiology, 2016, 184, 818-828.	1.6	21
267	Epilepsy, excess deaths and years of life lost from external causes. European Journal of Epidemiology, 2016, 31, 445-453.	2.5	21
268	National economic and development indicators and international variation in prostate cancer incidence and mortality: an ecological analysis. World Journal of Urology, 2017, 35, 851-858.	1.2	21
269	Cancer incidence among physicians occupationally exposed to ionizing radiation in Finland. Scandinavian Journal of Work, Environment and Health, 2006, 32, 368-373.	1.7	21
270	Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen. Clinical Cancer Research, 2003, 9, 2435-9.	3.2	21

#	Article	IF	CITATIONS
271	Effects of prostate cancer screening on health-related quality of life: Results of the Finnish arm of the European randomized screening trial (ERSPC). Acta Oncológica, 2013, 52, 1615-1621.	0.8	20
272	Family history in the <scp>F</scp> innish <scp>P</scp> rostate <scp>C</scp> ancer <scp>S</scp> creening <scp>T</scp> rial. International Journal of Cancer, 2015, 136, 2172-2177.	2.3	20
273	Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis. European Urology, 2016, 70, 372-381.	0.9	20
274	The Estonian Study of Chernobyl Cleanup Workers: I. Design and Questionnaire Data. Radiation Research, 1997, 147, 641.	0.7	19
275	Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. British Journal of Cancer, 2007, 96, 56-60.	2.9	19
276	Does the Imprecise Definition of Overactive Bladder Serve Commercial Rather than Patient Interests?. European Urology, 2012, 61, 746-748.	0.9	19
277	Non-cancer morbidity among Estonian Chernobyl cleanup workers: a register-based cohort study. BMJ Open, 2014, 4, e004516.	0.8	19
278	Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial. Prostate, 2015, 75, 1394-1402.	1.2	19
279	Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study. Acta Neurologica Scandinavica, 2009, 119, 55-60.	1.0	18
280	Cancer incidence in the vicinity of Finnish nuclear power plants: an emphasis on childhood leukemia. Cancer Causes and Control, 2010, 21, 587-595.	0.8	18
281	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. Journal of Medical Screening, 2013, 20, 33-38.	1.1	18
282	Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. British Journal of Cancer, 2018, 118, 1248-1254.	2.9	18
283	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	0.9	18
284	Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. PLoS ONE, 2016, 11, e0153413.	1.1	18
285	CASP8 D302H and meningioma risk: An analysis of five case-control series. Cancer Letters, 2009, 273, 312-315.	3.2	17
286	Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. International Journal of Cancer, 2012, 131, 1367-1375.	2.3	17
287	The Impact of Interscreening Interval and Age on Prostate Cancer Screening With Prostate-Specific Antigen. European Urology, 2012, 61, 1011-1018.	0.9	17
288	Synergistic Interaction of <i>HOXB13</i> and <i>CIP2A</i> Predisposes to Aggressive Prostate Cancer. Clinical Cancer Research, 2018, 24, 6265-6276.	3.2	17

#	Article	IF	CITATIONS
289	Should we start population screening for prostate cancer? Randomised trials are still needed. International Journal of Cancer, 2002, 97, 377-378.	2.3	16
290	Changes in prevalence of urinary symptoms in Finnish men. Scandinavian Journal of Urology and Nephrology, 2004, 38, 378-384.	1.4	16
291	No increase in thyroid cancer among children and adolescents in Finland due to Chernobyl accident. European Journal of Cancer, 2006, 42, 1167-1171.	1.3	16
292	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	1.3	15
293	Geographical differences in the prevalence of hypospadias in Finland. Environmental Research, 2003, 92, 118-123.	3.7	14
294	KLF6 IVS1 -27G>A Variant and the Risk of Prostate Cancer in Finland. European Urology, 2007, 52, 1076-1081.	0.9	14
295	A stochastic model for survival of early prostate cancer with adjustments for leadtime, length bias, and overâ€detection. Biometrical Journal, 2012, 54, 20-44.	0.6	14
296	A Different Method of Evaluation of the ERSPC Trial Confirms That Prostate-specific Antigen Testing Has a Significant Impact on Prostate Cancer Mortality. European Urology, 2014, 66, 401-403.	0.9	14
297	5â€Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. International Journal of Cancer, 2016, 138, 2820-2828.	2.3	14
298	Insulin glargine use and breast cancer risk: Associations with cumulative exposure. Acta Oncológica, 2016, 55, 851-858.	0.8	14
299	Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer. Cancer Epidemiology, 2016, 45, 1-5.	0.8	14
300	Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scandinavian Journal of Urology, 2016, 50, 413-419.	0.6	14
301	Occupational solvent exposure and adult chronic lymphocytic leukemia: No risk in a population-based case-control study in four Nordic countries. International Journal of Cancer, 2017, 141, 1140-1147.	2.3	14
302	An international prospective cohort study of mobile phone users and health (COSMOS): Factors affecting validity of self-reported mobile phone use. International Journal of Hygiene and Environmental Health, 2018, 221, 1-8.	2.1	14
303	Effects of incomplete residential histories on studies of environmental exposure with application to childhood leukaemia and background radiation. Environmental Research, 2018, 166, 466-472.	3.7	14
304	Epidemiological studies of natural sources of radiation and childhood cancer: current challenges and future perspectives. Journal of Radiological Protection, 2020, 40, R1-R23.	0.6	14
305	Cancer Incidence Among Finnish Nuclear Reactor Workers. Journal of Occupational and Environmental Medicine, 2002, 44, 634-638.	0.9	13
306	Retention rate of oxcarbazepine monotherapy in an unselected population of adult epileptics. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 72-74.	0.9	13

#	Article	IF	CITATIONS
307	Smoking causes erectile dysfunction through vascular disease. Urology, 2006, 68, 1318-1322.	0.5	13
308	Seizure-freedom with combination therapy in localization-related epilepsy. Seizure: the Journal of the British Epilepsy Association, 2008, 17, 276-280.	0.9	13
309	Mobile phone use and location of glioma: A case–case analysis. Bioelectromagnetics, 2009, 30, 176-182.	0.9	13
310	Validation of exposure assessment and assessment of recruitment methods for a prospective cohort study of mobile phone users (COSMOS) in Finland: a pilot study. Environmental Health, 2011, 10, 14.	1.7	13
311	Chernobyl fallout and cancer incidence in Finland 1988–2007. International Journal of Cancer, 2014, 134, 2253-2263.	2.3	13
312	Childhood leukaemia risks: from unexplained findings near nuclear installations to recommendations for future research. Journal of Radiological Protection, 2014, 34, R53-R68.	0.6	13
313	Eye Lens Opacities Among Physicians Occupationally Exposed to Ionizing Radiation. Annals of Occupational Hygiene, 2015, 59, 945-948.	1.9	13
314	Population attitudes towards research use of health care registries: a population-based survey in Finland. BMC Medical Ethics, 2015, 16, 48.	1.0	13
315	Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case–control study. Cancer Causes and Control, 2016, 27, 637-645.	0.8	13
316	Populationâ€based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. BJU International, 2022, 130, 193-199.	1.3	13
317	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022 35 59-67	0.2	13
318	Antimitochondrial antibodies in patients with epilepsy. Epilepsy and Behavior, 2005, 7, 95-97.	0.9	12
319	Estimating the Cosmic Radiation Dose for a Cabin Crew With Flight Timetables. Journal of Occupational and Environmental Medicine, 2007, 49, 540-545.	0.9	12
320	Evaluation of breast cancer service screening programme with a Bayesian approach: mortality analysis in a Finnish region. Breast Cancer Research and Treatment, 2010, 121, 671-678.	1.1	12
321	Application of the ELDO approach to assess cumulative eye lens doses for interventional cardiologists. Radiation Protection Dosimetry, 2015, 164, 84-88.	0.4	12
322	Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. British Journal of Cancer, 2016, 115, 1289-1295.	2.9	12
323	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS ONE, 2020, 15, e0234269.	1.1	12
324	Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. Scandinavian Journal of Work, Environment and Health, 2020, 46, 278-292.	1.7	12

#	Article	IF	CITATIONS
325	Multiple Approaches and Participation Rate for a Community Based Smoking Cessation Intervention Trial in Rural Kerala, India. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2891-2896.	0.5	12
326	Haemophilus influenzae type b vaccine formulation and risk of childhood leukaemia. British Journal of Cancer, 2002, 87, 511-512.	2.9	11
327	Prostate cancer risk among users of finasteride and alpha-blockers – A population based case–control study. European Journal of Cancer, 2007, 43, 775-781.	1.3	11
328	Asbestos-related pleural and lung fibrosis in patients with retroperitoneal fibrosis. Orphanet Journal of Rare Diseases, 2008, 3, 29.	1.2	11
329	Results of the three rounds of the Finnish Prostate Cancer Screening Trial—The incidence of advanced cancer is decreased by screening. International Journal of Cancer, 2010, 127, 1699-1705.	2.3	11
330	Prevalence and bother of postmicturition dribble in Finnish men aged 30–80 years: Tampere Ageing Male Urologic Study (TAMUS). Scandinavian Journal of Urology and Nephrology, 2012, 46, 418-423.	1.4	11
331	Excess all-cause mortality in the evaluation of a screening trial to account for selective participation. Journal of Medical Screening, 2013, 20, 39-45.	1.1	11
332	The Finnish prostate cancer screening trial: Analyses on the screening failures. International Journal of Cancer, 2015, 136, 2437-2443.	2.3	11
333	Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial. Cancer Causes and Control, 2016, 27, 157-164.	0.8	11
334	Impact of cause of death adjudication on the results of the European prostate cancer screening trial. British Journal of Cancer, 2017, 116, 141-148.	2.9	11
335	Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. International Journal of Urology, 2018, 25, 270-276.	0.5	11
336	Productivity losses associated with premature mortality due to cancer in Russia: A population-wide study covering 2001–2030. Scandinavian Journal of Public Health, 2019, 47, 482-491.	1.2	11
337	Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 453-460.	2.0	11
338	Incidence trends of adult malignant brain tumors in Finland, 1990–2016. Acta Oncológica, 2019, 58, 990-996.	0.8	11
339	Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. Prostate Cancer and Prostatic Diseases, 2019, 22, 317-323.	2.0	11
340	Cancer risk following radiotherapy for infertility or menstrual disorders. , 1999, 82, 795-798.		10
341	Test Sensitivity in the European Prostate Cancer Screening Trial: Results from Finland, Sweden, and the Netherlands. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2000-2005.	1.1	10
342	State of the art in research into the risk of low dose radiation exposure—findings of the fourth MELODI workshop. Journal of Radiological Protection, 2013, 33, 589-603.	0.6	10

#	Article	IF	CITATIONS
343	Incidence of Pediatric Inflammatory Bowel Disease in Finland. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 65-70.	0.9	10
344	Parental occupational exposure to low-frequency magnetic fields and risk of leukaemia in the offspring: findings from the Childhood Leukaemia International Consortium (CLIC). Occupational and Environmental Medicine, 2019, 76, 746-753.	1.3	10
345	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. Cancer Imaging, 2020, 20, 72.	1.2	10
346	Occupational radiation dose estimation for Finnish aircraft cabin attendants. Scandinavian Journal of Work, Environment and Health, 2004, 30, 157-163.	1.7	10
347	PREDICTORS OF BIOLOGICAL AGGRESSIVENESS OF PROSTATE SPECIFIC ANTIGEN SCREENING DETECTED PROSTATE CANCER. Journal of Urology, 2001, 165, 1569-1574.	0.2	9
348	The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening?. BJU International, 2003, 92, 14-16.	1.3	9
349	Why do men opt out of prostateâ€cancer screening? Attitudes and perception among participants and nonâ€participants of a screening trial. BJU International, 2010, 106, 472-477.	1.3	9
350	Empirical evaluation of grouping of lower urinary tract symptoms: principal component analysis of Tampere Ageing Male Urological Study data. BJU International, 2013, 111, 467-473.	1.3	9
351	Chernobyl cleanup workers from Estonia: cohort description and related epidemiological research. Journal of Radiological Protection, 2015, 35, R35-R45.	0.6	9
352	Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC). BJU International, 2016, 118, 677-680.	1.3	9
353	Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. BMC Cancer, 2017, 17, 585.	1.1	9
354	Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. Scandinavian Journal of Urology, 2018, 52, 321-327.	0.6	9
355	Excess mortality in Finnish diabetic subjects due to alcohol, accidents and suicide: a nationwide study. European Journal of Endocrinology, 2018, 179, 299-306.	1.9	9
356	Radiation doses from global fallout and cancer incidence among reindeer herders and Sami in Northern Finland. Occupational and Environmental Medicine, 2010, 67, 737-743.	1.3	8
357	Prevalence of hesitancy in 30–80â€yearâ€old Finnish men: Tampere Ageing Male Urological Study (TAMUS). BJU International, 2012, 109, 1360-1364.	1.3	8
358	Fallout from the Chernobyl accident and overall cancer incidence in Finland. Cancer Epidemiology, 2013, 37, 585-592.	0.8	8
359	Risk Factors for Skin Cancer among Finnish Airline Cabin Crew. Annals of Occupational Hygiene, 2013, 57, 695-704.	1.9	8
360	The effect of nonâ€steroidal antiâ€inflammatory drugs on risk of benign prostatic hyperplasia. Prostate, 2017, 77, 1029-1035.	1.2	8

#	Article	IF	CITATIONS
361	Costs of Robotic-Assisted Versus Traditional Laparoscopy in Endometrial Cancer. International Journal of Gynecological Cancer, 2017, 27, 1788-1793.	1.2	8
362	The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers. European Urology, 2019, 76, 276-279.	0.9	8
363	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	2.6	8
364	Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden. Journal of Neuro-Oncology, 2019, 141, 139-149.	1.4	8
365	A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. European Urology Focus, 2019, 5, 561-567.	1.6	8
366	Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast Cancer Research and Treatment, 2021, 187, 267-274.	1.1	8
367	Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial. Scandinavian Journal of Urology, 2021, 55, 348-353.	0.6	8
368	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. Journal of Medical Screening, 2013, 20, 33-38.	1.1	8
369	Biological aggressiveness of prostate cancer in the Finnish screening trial. International Journal of Cancer, 2009, 124, 547-552.	2.3	7
370	Assessing Interactions of Two Loci (rs4242382 and rs10486567) in Familial Prostate Cancer: Statistical Evaluation of Epistasis. PLoS ONE, 2014, 9, e89508.	1.1	7
371	Natural Course of Lower Urinary Tract Symptoms in Men Not Requiring Treatment–ÂA 5-Year Longitudinal Population-based Study. Urology, 2014, 83, 411-415.	0.5	7
372	Pituitary tumor risk in relation to mobile phone use: A case-control study. Acta Oncológica, 2015, 54, 1159-1165.	0.8	7
373	Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. European Urology, 2015, 68, 1089-1097.	0.9	7
374	Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer and Prostatic Diseases, 2018, 21, 373-378.	2.0	7
375	Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. European Urology, 2019, 75, 1015-1022.	0.9	7
376	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). Clinical Cancer Research, 2019, 25, 839-843.	3.2	7
377	Age-, sex- and disease subtype–related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. European Journal of Cancer, 2020, 130, 1-11.	1.3	7
378	A cohort study on adult hematological malignancies and brain tumors in relation to magnetic fields from indoor transformer stations. International Journal of Hygiene and Environmental Health, 2021, 233, 113712.	2.1	7

#	Article	IF	CITATIONS
379	Prostate Cancer Screening: A Survey of Attitudes and Practices among Finnish Physicians in 1999 and 2007. Journal of Medical Screening, 2011, 18, 46-49.	1.1	6
380	Population-level and Individual-level Bother of Lower Urinary Tract Symptoms Among 30- to 80-year-old Men. Urology, 2016, 95, 164-170.	0.5	6
381	Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. European Urology, 2016, 70, 499-505.	0.9	6
382	Residential mobility and the risk of childhood leukemia. Cancer Causes and Control, 2016, 27, 433-443.	0.8	6
383	Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. Prostate Cancer and Prostatic Diseases, 2019, 22, 483-490.	2.0	6
384	Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. PLoS ONE, 2019, 14, e0224479.	1.1	6
385	Patients' education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer. European Journal of Cancer, 2020, 130, 204-210.	1.3	6
386	Pharmacoepidemiological Evaluation in Prostate Cancer—Common Pitfalls and How to Avoid Them. Cancers, 2021, 13, 696.	1.7	6
387	Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer. Cancer Causes and Control, 2021, 32, 1299-1313.	0.8	6
388	The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. European Urology Focus, 2021, 7, 943-946.	1.6	6
389	Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. JAMA Oncology, 2022, 8, 61.	3.4	6
390	Lower Urinary Tract Symptoms and Mortality among Finnish Men: The Roles of Symptom Severity and Bother. Journal of Urology, 2022, 207, 1285-1294.	0.2	6
391	Randomized Screening Trial for Prostate Cancer in Finland. European Urology, 2001, 39, 32-32.	0.9	5
392	Fine mapping of 11q13.5 identifies regions associated with prostate cancer and prostate cancer death. European Journal of Cancer, 2013, 49, 3335-3343.	1.3	5
393	Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. European Urology Focus, 2018, 4, 851-857.	1.6	5
394	Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer. Cancer Causes and Control, 2019, 30, 877-888.	0.8	5
395	Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer and Prostatic Diseases, 2021, 24, 1158-1166.	2.0	5
396	Comparability and validity of cancer registry data in the northwest of Russia. Acta Oncológica, 2021, 60, 1264-1271.	0.8	5

#	Article	IF	CITATIONS
397	Associations between systemic medications and development of wet ageâ€related macular degeneration. Acta Ophthalmologica, 2022, 100, 572-582.	0.6	5
398	Incidence of myelodysplastic syndromes in Finland 1997–2016. Leukemia Research, 2022, 116, 106839.	0.4	5
399	Cancer screening simulation models: a state of the art review. BMC Medical Informatics and Decision Making, 2021, 21, 359.	1.5	5
400	Temporal and Other Exposure Aspects of Residential Magnetic Fields Measurement in Relation to Acute Lymphoblastic Leukaemia in Children: The National Cancer Institute Children's Cancer Group Study. Radiation Protection Dosimetry, 1999, 83, 53-60.	0.4	4
401	Reliability and validity of a bioimpedance measurement device in the assessment of UVR damage to the skin. Archives of Dermatological Research, 2008, 300, 253-261.	1.1	4
402	RE: Prostate-Specific Antigen Screening Trials and Prostate Cancer Deaths: The Androgen Deprivation Connection. Journal of the National Cancer Institute, 2014, 106, .	3.0	4
403	Autoimmunity-related immunological serum markers and survival in a tertiary care cohort of adult patients with epilepsy. Epilepsy Research, 2014, 108, 1675-1679.	0.8	4
404	Prostate cancer screening in Europe – Authors' reply. Lancet, The, 2015, 385, 1507-1508.	6.3	4
405	Estimation of occupational cosmic radiation exposure among airline personnel: Agreement between a jobâ€exposure matrix, aggregate, and individual dose estimates. American Journal of Industrial Medicine, 2017, 60, 386-393.	1.0	4
406	Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. European Journal of Cancer, 2018, 93, 108-118.	1.3	4
407	Fertility and marital status in adults with childhood onset epilepsy: A populationâ€based cohort study. Epilepsia, 2019, 60, 1438-1444.	2.6	4
408	Longâ€ŧerm healthâ€related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. Cancer Medicine, 2020, 9, 5643-5654.	1.3	4
409	Trends and predictors in all-cause and cause-specific mortality in diabetic and reference populations during 21 years of follow-up. Journal of Epidemiology and Community Health, 2020, 74, jech-2019-213602.	2.0	4
410	Number of screening rounds attended and incidence of highâ€risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Cancer, 2021, 127, 188-192.	2.0	4
411	Exposure to loud noise and risk of vestibular schwannoma: results from the INTERPHONE international case‒control study. Scandinavian Journal of Work, Environment and Health, 2019, 45, 183-193.	1.7	4
412	Indoor radon and deaths from lung cancer. BMJ: British Medical Journal, 2009, 338, a3128-a3128.	2.4	4
413	Sauna habits/bathing and changes in lower urinary tract symptoms – Tampere Ageing Male Urologic Study (TAMUS). Scandinavian Journal of Urology, 2022, 56, 77-82.	0.6	4
414	Reply: Mobile phone use and acoustic neuroma in five North European countries. British Journal of Cancer, 2006, 94, 1352-1353.	2.9	3

#	Article	IF	CITATIONS
415	Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study. Acta Neurologica Scandinavica, 2008, 117, 332-336.	1.0	3
416	What explains the differences between centres in the European screening trial? A simulation study. Cancer Epidemiology, 2017, 46, 14-19.	0.8	3
417	Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use. Journal of Urology, 2017, 198, 305-309.	0.2	3
418	Biasâ€corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. International Journal of Cancer, 2019, 145, 632-638.	2.3	3
419	Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. European Urology Focus, 2019, 5, 186-191.	1.6	3
420	Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. Cancers, 2021, 13, 435.	1.7	3
421	Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 982-989.	1.1	3
422	Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. International Journal of Cancer, 2021, 149, 307-315.	2.3	3
423	Trends of computed tomography use among children in Finland. European Journal of Radiology Open, 2020, 7, 100290.	0.7	3
424	Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level. Cancers, 2022, 14, 2920.	1.7	3
425	Incidence trends of childhood central nervous system tumors in Finland 1990–2017. BMC Cancer, 2022, 22, .	1.1	3
426	Lung cancer risk from indoor radon. Lancet, The, 1996, 348, 1662-1663.	6.3	2
427	Response: Re: Time Trends in Brain Tumor Incidence Rates in Denmark, Finland, Norway, and Sweden, 1974–2003. Journal of the National Cancer Institute, 2010, 102, 742-743.	3.0	2
428	Foreword: Meeting the challenge of prostate cancer. European Journal of Cancer, 2010, 46, 3037-3039.	1.3	2
429	Effect of intervention on decision making of treatment for disease progression, prostateâ€ <b>s</b> pecific antigen biochemical failure and prostate cancer death. Health Expectations, 2014, 17, 776-783.	1.1	2
430	Prostate cancer screening using risk stratification based on a multiâ€state model of genetic variants. Prostate, 2015, 75, 825-835.	1.2	2
431	Bayesian negative-binomial-family-based multistate Markov model for the evaluation of periodic population-based cancer screening considering incomplete information and measurement errors. Statistical Methods in Medical Research, 2018, 27, 2519-2539.	0.7	2
432	Prostate cancer screening: what can we learn from randomised trials?. Translational Andrology and Urology, 2018, 7, 12-17.	0.6	2

#	Article	IF	CITATIONS
433	Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. Scientific Reports, 2018, 8, 10308.	1.6	2
434	Diagnostic radiological examinations and risk of intracranial tumours in adults—findings from the Interphone Study. International Journal of Epidemiology, 2022, 51, 537-546.	0.9	2
435	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. European Urology Open Science, 2021, 30, 47-62.	0.2	2
436	Methodological considerations for interrupted time series analysis in radiation epidemiology: an overview. Journal of Radiological Protection, 2021, 41, 609-618.	0.6	2
437	USE OF THE COMPLEX BETWEEN PROSTATE SPECIFIC ANTIGEN AND ??1-PROTEASE INHIBITOR FOR SCREENING PROSTATE CANCER. Journal of Urology, 2000, , 1956-1960.	0.2	2
438	Association of allergic diseases and epilepsy with risk of glioma, meningioma and acoustic neuroma: results from the INTERPHONE international case–control study. European Journal of Epidemiology, 2022, 37, 503-512.	2.5	2
439	Prostate cancer screening. Lancet, The, 2001, 357, 1201.	6.3	1
440	Reliability and Validity of Prostate-Specific Antigen. JAMA - Journal of the American Medical Association, 2003, 290, 1705.	3.8	1
441	Validity and reliability of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus: Comment on the article by Kozora et al. Arthritis and Rheumatism, 2005, 53, 478-479.	6.7	1
442	Early detection of skin cancer as public health policy: Comparison of campaign and routine activity. Preventive Medicine, 2008, 46, 160-165.	1.6	1
443	PC DETECTION IN MEN WITH INITIAL PSA LEVELS < 3.0 NG/ML. DATA FROM ERSPC 1993- 2007. Journal of Urology, 2009, 181, 646.	0.2	1
444	Number needed to screen—How can we project outside context?. Journal of Clinical Epidemiology, 2011, 64, 1275-1276.	2.4	1
445	Outcomes of medical and surgical treatment for lower urinary tract symptoms (benign prostatic) Tj ETQq1 1 0.78 349-355.	4314 rgB 0.8	T /Overlock 1
446	PD31-03 STATIN USE AND SURVIVAL AFTER PROSTATE CANCER DIAGNOSIS IN THE FINNISH PROSTATE CANCER SCREENING TRIAL. Journal of Urology, 2014, 191, .	0.2	1
447	Cancer Screening: Theory and Applications. , 2017, , 389-405.		1
448	Severity and bother of lower urinary tract symptoms among men aged 30–80Âyears: Tampere Ageing Male Urological Study (TAMUS). Scandinavian Journal of Urology, 2018, 52, 296-301.	0.6	1
449	Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening. Scientific Reports, 2020, 10, 20665.	1.6	1
450	Seasonal changes in occurrence and severity of lower urinary tract symptoms—Tampere Aging Male Urologic Study ( TAMUS ). LUTS: Lower Urinary Tract Symptoms, 2021, 13, 216-223.	0.6	1

#	Article	IF	CITATIONS
451	Abstract 4226: Association between NSAID, statins, and bisphosphonates and prostate cancer survival during androgen deprivation therapy. , 2018, , .		1
452	Epidemiologic Assessment of Cancer Risk from Mobile Phone Use: Where are We. Progress in Electromagnetics Research Symposium: [proceedings] Progress in Electromagnetics Research Symposium, 2006, 2, 197-199.	0.4	1
453	Are There Limits in Explainability of Prognostic Biomarkers? Scrutinizing Biological Utility of Established Signatures. Cancers, 2021, 13, 5087.	1.7	1
454	1719: Statins and Prostate Cancer Among Men Participating in the Finnish Prostate Cancer Screening Trial. Journal of Urology, 2007, 177, 572-572.	0.2	1
455	Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer. European Urology Open Science, 2021, 34, 27-32.	0.2	1
456	Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. British Journal of Cancer, 2022, , .	2.9	1
457	The effect of breast self-examination on breast cancer survival. Patient Education and Counseling, 1991, 18, 279.	1.0	0
458	Colon Cancer Survival in Finland. Cancer, 1993, 71, 2884-2885.	2.0	0
459	MAJOR RISK FACTORS FOR NOCTURIA IN A POPULATION- BASED STUDY. Journal of Urology, 2008, 179, 540-541.	0.2	0
460	INCIDENCE OF ADVANCED PROSTATE CANCER IN THE FINNISH PROSTATE CANCER SCREENING TRIAL. Journal of Urology, 2008, 179, 598-598.	0.2	0
461	BOTHER AND IMPACT OF NOCTURIA ON HEALTH-RELATED QUALITY OF LIFE. Journal of Urology, 2008, 179, 112-112.	0.2	0
462	More Study Needed on Morning Erections and Erectile Dysfunction. American Journal of Medicine, 2009, 122, e7-e8.	0.6	0
463	IMPACT OF OVERACTIVE BLADDER DRY AND WET ON HEALTH-RELATED QUALITY OF LIFE: A POPULATION-BASED STUDY. Journal of Urology, 2009, 181, 86-86.	0.2	0
464	Author's Response: Response to commentary: Meningioma and mobile phone use–a collaborative case-control study in five North European countries. International Journal of Epidemiology, 2010, 39, 1119-1119.	0.9	0
465	Prostate cancer and deprivation. BMJ: British Medical Journal, 2010, 340, c2043-c2043.	2.4	0
466	1763 ARE URINARY STORAGE SYMPTOMS RELATED WITH SMOKING? A POPULATION-BASED STUDY IN WOMEN. Journal of Urology, 2010, 183, .	0.2	0
467	971 INTERVAL CANCERS IN THE SCREENING OF PROSTATE CANCER: RESULTS FROM THE HELSINKI AREA OF THE ERSPC STUDY. European Urology Supplements, 2010, 9, 304-305.	0.1	0
468	1955 WHAT IS THE MOST BOTHERSOME LOWER URINARY TRACT SYMPTOM? INDIVIDUAL AND POPULATION LEVEL PERSPECTIVES. Journal of Urology, 2011, 185, .	0.2	0

#	Article	IF	CITATIONS
469	25 THE SCREENING TEST NEGATIVE INTERVAL CANCERS CAUSE MORE MORTALITY THAN THE SCREENING TEST POSITIVES. European Urology Supplements, 2011, 10, 36-37.	0.1	0
470	PD6-02 5-ALPHA REDUCTASE INHIBITOR USE AND PROSTATE CANCER SURVIVAL IN THE FINNISH PROSTATE CANCER SCREENING TRIAL. Journal of Urology, 2015, 193, .	0.2	0
471	PD6-09 POLYMORPHISMS IN GENES OF THE GLUCOSE- AND ENERGY-METABOLISM PATHWAYS AND PROSTATE CANCER: INTERPLAY WITH METFORMIN. Journal of Urology, 2015, 193, .	0.2	0
472	Prudent practice optimizes screening outcomes. Nature Reviews Urology, 2016, 13, 376-377.	1.9	0
473	PD09-04 ESTIMATING THE HARMS AND BENEFITS OF PROSTATE CANCER SCREENING: COMPARING COMMON CLINICAL PRACTICE TO RECOMMENDED GOOD PRACTICE. Journal of Urology, 2016, 195, .	0.2	0
474	PD09-01 CORRELATION BETWEEN STAGE SHIFT AND DIFFERENCES IN MORTALITY BETWEEN THE TWO STUDY ARMS OF THE ERSPC Journal of Urology, 2016, 195, .	0.2	0
475	PD40-06 A FOUR-KALLIKREIN PANEL IN PREDICTING HIGH-GRADE PROSTATE CANCER ON BIOPSY: AN INDEPENDENT REPLICATION FROM THE FINNISH SECTION OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER Journal of Urology, 2017, 197, .	0.2	0
476	PD40-03 EFFECT OF 5-ALFA REDUCTASE INHIBITOR USAGE ON OUTCOMES OF PROSTATE CANCER SCREENING. Journal of Urology, 2017, 197, .	0.2	0
477	PD47-02 FASTING BLOOD GLUCOSE AND PROSTATE CANCER RISK IN THE FINNISH RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.2	0
478	OBSOLETE: Cancer Screening: Theory and Applications. , 2019, , .		0
479	Impact of cancer screening on metastasis: A prostate cancer case study. Journal of Medical Screening, 2021, 28, 096914132198973.	1.1	0
480	1790: Determining Cause of Death in Prostate Cancer Screening. Journal of Urology, 2004, 171, 473-473.	0.2	0
481	462: Antidiabetic Medication and Prostate Cancer Risk - A Population-Based Case-Control Study. Journal of Urology, 2007, 177, 155-155.	0.2	0
482	69: Prevalence of Overactive Bladder is Overestimated. Journal of Urology, 2007, 177, 24-24.	0.2	0
483	TU-A-116-10: Dosimetry Approach for a Retrospective Epidemiological Study On Eye Lens Dose to Interventional Cardiologists and the Occurrence of Radiation-Induced Lens Opacities. Medical Physics, 2013, 40, 428-428.	1.6	0
484	Malignant Tumors of the Central Nervous System. , 2014, , 481-495.		0
485	Abstract 4681: Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish arm of the European randomised study of screening for prostate cancer (ERSPC). , 2015, , .		0
486	Abstract 3290: Cancer mortality by antiarrhythmic drug use in a population-based cohort of Finnish men. , 2017, , .		0

#	Article	IF	CITATIONS
487	Spatio-Temporal Clustering of Childhood Leukemia Relative to Population Mixing in Finland: A Nationwide Register-Based Study. Blood, 2019, 134, 5070-5070.	0.6	0
488	Malignant Tumors of the Central Nervous System. , 2020, , 507-524.		0
489	Title is missing!. , 2019, 14, e0224479.		0
490	Title is missing!. , 2019, 14, e0224479.		0
491	Title is missing!. , 2019, 14, e0224479.		0
492	Title is missing!. , 2019, 14, e0224479.		0
493	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
494	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
495	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
496	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0